Jager, Agnes

Associations of breast cancer risk factors with tumor subtypes: A pooled analysis from the breast cancer association consortium studies

Yang, X. R., Chang-Claude, J., Goode, E. L., Couch, F. J., Nevanlinna, H., Milne, R. L., Gaudet, M., Schmidt, M. K., Broeks, A., Cox, A., et al. (2011) · JNCI: Journal of the National Cancer Institute

Cancer Risks and FactorsBreast Cancer Treatment Studies

Cited by 691

Low muscle attenuation is a prognostic factor for survival in metastatic breast cancer patients treated with first line palliative chemotherapy

Rier, H. N., Jager, A., Sleijfer, S., van Rosmalen, J., Kock, M. C. J. M., & Levin, M.-D. (2017) · The Breast

Nutrition and Health in AgingBody Composition Measurement Techniques

Cited by 149

Pharmacological CDK4/6 inhibition reveals a p53‐dependent senescent state with restricted toxicity

Wang, B., Varela‐Eirin, M., Brandenburg, S. M., Hernandez‐Segura, A., van Vliet, T., Jongbloed, E. M., Wilting, S. M., Ohtani, N., Jager, A., & Demaria, M. (2022) · The EMBO Journal

Telomeres, Telomerase, and SenescenceCancer-related Molecular Pathways

Cited by 113

Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC).

Sonke, G. S., Van Ommen - Nijhof, A., Wortelboer, N., van der Noort, V., Swinkels, A. C. P., Blommestein, H. M., Beeker, A., Beelen, K., Hamming, L. C., Heijns, J. B., et al. (2023) · Journal of Clinical Oncology

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 88

The risk of primary and contralateral breast cancer after ovarian cancer in BRCA1/BRCA2 mutation carriers: Implications for counseling

Vencken, P. M. L. H., Kriege, M., Hooning, M., Menke‐Pluymers, M. B., Heemskerk‐Gerritsen, B. A. M., van Doorn, L. C., Collée, M. M., Jager, A., van Montfort, C., Burger, C. W., et al. (2013) · Cancer

BRCA gene mutations in cancerMultiple and Secondary Primary Cancers

Cited by 40

Potential cost savings owing to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the Netherlands

Franken, M. G., Kanters, T. A., Coenen, J. L., de Jong, P., Koene, H. R., Lugtenburg, P. J., Jager, A., & Uyl-de Groot, C. A. (2018) · Anti-Cancer Drugs

Economic and Financial Impacts of CancerHealth Systems, Economic Evaluations, Quality of Life

Cited by 37

Relation of Impaired Fasting and Postload Glucose With Incident Type 2 Diabetes in a Dutch Population: The Hoorn Study

de Vegt, F., Dekker, J. M., Jager, A., Hienkens, E., Kostense, P. J., Stehouwer, C. D. A., Nijpels, G., Bouter, L. M., & Heine, R. J. (2001) · JAMA

Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Management and Research

Cited by 10

Machine learning-based somatic variant calling in cell-free DNA of metastatic breast cancer patients using large NGS panels

Jongbloed, E. M., Jansen, M. P. H. M., de Weerd, V., Helmijr, J. A., Beaufort, C. M., Reinders, M. J. T., van Marion, R., van IJcken, W. F. J., Sonke, G. S., Konings, I. R., et al. (2023) · Scientific Reports

Cancer Genomics and DiagnosticsGenomics and Rare Diseases

Cited by 6